Autoimmunity reviews最新文献

{"title":"Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions","authors":"Emre Bilgin ,&nbsp;Vincenzo Venerito ,&nbsp;Dimitrios P. Bogdanos","doi":"10.1016/j.autrev.2025.103864","DOIUrl":"10.1016/j.autrev.2025.103864","url":null,"abstract":"<div><div>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have improved the management of type 2 diabetes and obesity. Increasing evidence suggests their potential therapeutic role in rheumatic and musculoskeletal diseases, yet their precise mechanisms and clinical implications remain under investigation. This scoping review evaluates the current evidence on GLP-1 RAs in inflammatory arthritis, osteoarthritis, systemic autoimmune diseases, and other rheumatic conditions. This systematic literature search followed PRISMA-ScR guidelines and identified 52 studies and seven clinical trials from Scopus, PubMed, and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>. Although most of the included studies had a risk of bias, the findings suggest that GLP-1 RAs may influence inflammatory pathways, oxidative stress, and immune regulation in conditions such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), osteoarthritis (OA), and gout. In RA and PsA, GLP-1 RAs have demonstrated potential disease-modifying effects, reducing inflammatory cytokine expression and improving metabolic parameters; however, their clinical impact remains partially linked to weight loss. Studies on OA indicate chondroprotective and anti-inflammatory properties, yet their effect on disease progression remains inconclusive.</div><div>Additionally, GLP-1 RAs have been associated with cardiovascular and renal benefits in SLE, though concerns about autoimmune activation persist. Despite promising findings, several challenges remain, including heterogeneous clinical responses, the need for head-to-head comparisons with standard rheumatologic therapies, and a lack of long-term safety data in autoimmune conditions. Drug-induced autoimmune phenomena, cost considerations, and accessibility limitations must be addressed. Future research should focus on distinguishing between metabolic and direct immunomodulatory effects, optimizing combination therapies, and evaluating safety concerns. GLP-1 RAs hold potential as a novel therapeutic approach in rheumatology, but further well-designed randomized controlled trials are essential to establish their clinical role.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103864"},"PeriodicalIF":9.2,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological patterns and in-hospital mortality in ANCA-associated vasculitis: Insights from Spain's National Health Data (2016–2022)","authors":"Francisco-Josué Cordero-Pérez ,&nbsp;Pablo Martínez-Rodríguez ,&nbsp;Luis Arribas-Pérez ,&nbsp;David Puertas-Miranda ,&nbsp;Carlos-Rafael Pires-Baltazar ,&nbsp;Leticia Salcedo-Martín ,&nbsp;Juan Antonio Sánchez-Villoria ,&nbsp;Erik Gabriel Díaz-Ávila ,&nbsp;Hugo-Guillermo Ternavasio-De La Vega ,&nbsp;Miguel Marcos ,&nbsp;Antonio-Javier Chamorro","doi":"10.1016/j.autrev.2025.103863","DOIUrl":"10.1016/j.autrev.2025.103863","url":null,"abstract":"<div><h3>Background</h3><div>ANCA-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), is a systemic autoimmune disease. This study represents the first large-scale analysis of AAV hospitalisation rates and in-hospital mortality trends in Spain.</div></div><div><h3>Methods</h3><div>A retrospective longitudinal analysis of AAV-related hospital admissions between 2016 and 2022 was conducted using the ICD-10 codes from the Minimum Basic Dataset (MBDS) of the Spanish National Health System. Statistical analyses were performed, including odds ratios, Student's <em>t</em>-tests, and Mantel-Haenszel trend tests.</div></div><div><h3>Results</h3><div>Among 5753 AAV episodes, GPA was the most frequent subtype (53.9 %), followed by MPA (31.5 %) and EGPA (14.6 %). AAV episodes were more frequent in older patients (&gt; 65 years) than in other hospital episodes (62.9 % vs. 38.9 %; OR: 2.66, 95 %CI: 2.51–2.80; <em>P</em> &lt; 0.001). Larger hospitals accounted for more AAV episodes, longer hospital stays, and higher costs. MPA had the highest mortality rate (7.2 % vs. 4.9 %; OR: 1.52, 95 % CI: 1.27–1.79; <em>P</em> &lt; 0.001), particularly in patients over 65 years (83.1 % vs. 61.8 %; OR: 3.04, 95 % CI: 2.47–3.75; <em>P</em> &lt; 0.001) compared with the other AAV. In the GPA group, renal involvement significantly increased mortality compared to GPA cases without renal involvement (6.6 % vs. 4.6 %; OR: 1.46, 95 % CI: 1.16–1.83; <em>P</em> = 0.011). Notably, the relative risk of AAV-related deaths increased over the study period (Z = 2.77, <em>P &lt;</em> 0.01).</div></div><div><h3>Conclusion</h3><div>AAV, particularly MPA, is associated with increased hospital mortality, particularly among older adults and patients with renal involvement.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103863"},"PeriodicalIF":9.2,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of monoclonal anti-TNF antibodies in the treatment of vascular Behçet's syndrome: A systematic review and meta-analysis","authors":"Yeling Liu ,&nbsp;Jingwen Wu ,&nbsp;Yiyuan Ao ,&nbsp;Lu Li ,&nbsp;Xiaoou Wang ,&nbsp;Menghao Zhang ,&nbsp;Xin Yu ,&nbsp;Luxi Sun ,&nbsp;Jinjing Liu ,&nbsp;Wenjie Zheng","doi":"10.1016/j.autrev.2025.103862","DOIUrl":"10.1016/j.autrev.2025.103862","url":null,"abstract":"<div><h3>Objectives</h3><div>This study is the first meta-analysis to evaluate the efficacy and safety of monoclonal anti-TNF antibodies in patients with vascular Behçet's syndrome (VBS).</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted on PubMed, Embase, Cochrane Library, Medline Complete, and Web of Science. Pooled estimates of clinical response including complete response (CR) and partial response (PR), were calculated at 3, 6, and 12 months. Subgroup analyses were performed based on the specific monoclonal anti-TNF antibodies used. Additionally, pooled proportions of imaging response before and after 6 months were assessed.</div></div><div><h3>Results</h3><div>Twelve studies involving 297 patients were included. The pooled proportions of clinical CR were 64.1 % (95 %CI 28.7–93.9 %), 89.1 % (95 %CI 72.4–98.6 %), and 94.5 % (95 %CI 82.5–99.8 %) at 3, 6, and 12 months, respectively. Imaging response was achieved in 92.9 % (95 %CI 77.2–100 %) of patients within 6 months and 92.5 % (95 %CI 74.8–99.9 %) after 6 months. During follow-up, 26 patients experienced a relapse while on monoclonal anti-TNF antibodies treatment. Of the 43 patients who discontinued therapy due to response, 28 % (<em>n</em> = 12) experienced a relapse. Adverse events (AEs) were reported in 10 studies involving 42 patients, with 31 patients experiencing severe AEs, including 5 deaths.</div></div><div><h3>Conclusions</h3><div>Monoclonal anti-TNF antibodies are an effective treatment for VBS, demonstrating significant clinical and radiological efficacy with a favorable safety profile. Prevention of relapses and control of disease progression remain critical objectives in VBS management. Further validation of their efficacy through randomized controlled trials (RCTs) stratified by arterial and venous involvement is warranted to strengthen the evidence base and optimize therapeutic strategies.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103862"},"PeriodicalIF":9.2,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy","authors":"Ruifan Wen ,&nbsp;Binbin Li ,&nbsp;Feifeng Wu ,&nbsp;Jueyi Mao ,&nbsp;Tasnim Azad ,&nbsp;Yang Wang ,&nbsp;Junquan Zhu ,&nbsp;Xin Zhou ,&nbsp;Haotian Xie ,&nbsp;Xinying Qiu ,&nbsp;Marady Hun ,&nbsp;Jidong Tian ,&nbsp;Liang Zhang ,&nbsp;Kimsor Hong ,&nbsp;Chuan Wen","doi":"10.1016/j.autrev.2025.103859","DOIUrl":"10.1016/j.autrev.2025.103859","url":null,"abstract":"<div><div>Currently, autoimmune disorders are predominantly managed with broad-spectrum immunosuppressive agents and monoclonal antibodies, which can alleviate disease symptoms but are rarely curative and are frequently associated with significant adverse effects. Autoreactive B cells play a key role in the pathogenesis of many autoimmune diseases; however, B-cell-depleting therapies such as rituximab have shown limited efficacy in certain autoimmune diseases, primarily due to the persistence of autoreactive B cells within lymphoid tissues and sites of inflammation. Consequently, there is an urgent need for more effective and targeted therapies for patients with severe and refractory autoimmune conditions. In this context, recent advancements in genetic engineering have facilitated the application of cell-based therapies, which have transitioned from oncology to treating autoimmune diseases. Therapies utilizing chimeric antigen receptor (CAR) engineered immune cells have emerged as a promising and potentially curative approach. Clinical trials targeting CD19-expressing B cells in B cell–driven autoimmune diseases, such as systemic lupus erythematosus (SLE), have yielded encouraging results, demonstrating durable remissions in otherwise treatment-resistant cases. In addition, novel strategies are being developed to broaden the therapeutic scope of CAR-based therapies in autoimmunity, including chimeric autoantibody receptor (CAAR)-T cells designed to eliminate autoantigen-specific B cells selectively and CAR-engineered regulatory T cells (CAR-Tregs) aimed at achieving antigen-specific immune modulation and restoration of self-tolerance. Despite these advances, several challenges persist, including short and long-term safety concerns, limited in vivo persistence, and the high costs associated with personalized cell manufacturing. Innovations in CAR design, such as logic-gated CARs, inducible suicide switches, and universal CAR constructs, are under active investigation to enhance safety, control, scalability, and clinical accessibility.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103859"},"PeriodicalIF":9.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious agents in dilated cardiomyopathy: Genetic interactions, autoimmunity, mechanisms, and therapeutic approaches","authors":"Jingdi Zhang,&nbsp;Haoting Zhan,&nbsp;Honglin Xu,&nbsp;Rongrong Wang,&nbsp;Zhan Li,&nbsp;Futai Feng,&nbsp;Hongzheng Wu,&nbsp;Zhixin Xu,&nbsp;Siyu Wang,&nbsp;Ye Guo,&nbsp;Yongzhe Li","doi":"10.1016/j.autrev.2025.103860","DOIUrl":"10.1016/j.autrev.2025.103860","url":null,"abstract":"<div><div>Dilated cardiomyopathy (DCM) is a heterogeneous myocardial disorder characterized by left ventricular dilation and systolic dysfunction in the absence of ischemic, hypertensive, or valvular heart disease. Although its precise etiology remains unclear, it is widely recognized as a multifactorial disease arising from complex interactions between genetic predisposition and environmental triggers. Among these, infectious agents have been implicated in the pathogenesis of various subtypes, particularly inflammatory and idiopathic DCM. These agents can contribute to disease onset and progression through direct cardiomyocyte injury, immune-mediated chronic inflammation, and other yet-to-be-defined mechanisms. Infection-driven autoimmune activation is another potential key contributor to DCM, potentially linking infectious exposure to sustained myocardial damage. However, the precise role of various infectious agents in DCM initiation and progression, as well as their interactions with genetic predisposition and autoimmune activation, is inadequately understood. Improving understanding of infection-related etiologies could facilitate development of targeted therapeutic strategies; however, significant challenges persist in identifying causative and novel pathogens, and translating this into clinical practice. Therefore, this review explores the complex interactions between infectious agents, genetic predisposition, and autoimmune responses in DCM pathogenesis. We summarize current evidence on the role of infectious agents in DCM and emerging therapeutic strategies aimed at treating infection-related DCM. Finally, we outline future research directions to advance understanding of infection-associated DCM and improve patient outcomes. We reveal that a deeper understanding of host-microbe interactions, immune pathways, and genetic predisposition is essential for advancing DCM research. Furthermore, integrating genomics, metagenomics, and antibody and immunological profiling is crucial for developing personalized therapeutic strategies for this complex disease.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103860"},"PeriodicalIF":9.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal stem cell in immunomodulation of dendritic cells: Implications for inflammatory bowel disease therapy","authors":"Dongqin Song ,&nbsp;Chang'e He ,&nbsp;Dickson Kofi Wiredu Ocansey ,&nbsp;Bo Wang ,&nbsp;Yunbing Wu ,&nbsp;Fei Mao","doi":"10.1016/j.autrev.2025.103861","DOIUrl":"10.1016/j.autrev.2025.103861","url":null,"abstract":"<div><div>Inflammatory bowel disease (IBD) is a highly prevalent and recurrent autoimmune disorder characterized by dysregulation of the immune system leading to intestinal inflammation. Currently, available clinical treatments, such as mesalazine, are mainly used to alleviate symptoms but do not cure the disease. Mesenchymal stem cells (MSCs), as an emerging therapeutic tool, show potential in IBD through immunomodulatory effects, but their specific mechanisms need further exploration. Dendritic cells (DCs) are important antigen-presenting cells that play a key role in the immune response in IBD, although their specific mechanism of action remains largely uncovered. This review focuses on discussing MSCs and their derived exosomes in the modulation of DC in IBD, providing insight into the therapeutic potentials of MSCs in IBD.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103861"},"PeriodicalIF":9.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact and management of warm autoimmune haemolytic anaemia associated with systemic lupus erythematosus","authors":"Guillermo J. Pons-Estel ,&nbsp;Marta Mosca ,&nbsp;Daniel J. Wallace ,&nbsp;Federico Zazzetti ,&nbsp;Ann Leon ,&nbsp;Wim Noël ,&nbsp;Andreia Pierce ,&nbsp;Tarek Ebrahim ,&nbsp;Irina Murakhovskaya","doi":"10.1016/j.autrev.2025.103858","DOIUrl":"10.1016/j.autrev.2025.103858","url":null,"abstract":"<div><div>Warm autoimmune haemolytic anaemia (wAIHA) is a rare autoantibody-mediated disorder that may occur in association with systemic lupus erythematosus (SLE). The clinical course of wAIHA is highly variable, ranging from anaemia compensated adequately by reticulocytosis to severe, life-threatening cases. While insights into the pathogenesis of wAIHA in SLE remain limited, emerging evidence highlights the risk factors and impact of wAIHA in the context of SLE. Management of wAIHA associated with SLE remains challenging as there is limited clinical evidence to support treatment decisions. New therapies, some that target underlying disease mechanisms relevant to both conditions, are in development. In this review, we examine the impact of wAIHA on clinical outcomes for patients with SLE, summarise the current management strategies along with unmet needs, and provide an update on novel therapeutic strategies.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103858"},"PeriodicalIF":9.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases – a systematic review","authors":"Mads Bundgaard-Nielsen ,&nbsp;Rikke Helin Johnsen ,&nbsp;Jann Mortensen ,&nbsp;Saher Burhan Shaker ,&nbsp;Christoffer Tandrup Holst Nielsen","doi":"10.1016/j.autrev.2025.103856","DOIUrl":"10.1016/j.autrev.2025.103856","url":null,"abstract":"<div><h3>Background</h3><div>Currently, no tools can monitor ongoing fibrotic activity properly, making early identification of and timely therapeutic intervention with antifibrotics in patients with progressive fibrosing interstitial lung disease (ILD) difficult. Fibroblast activation protein-α inhibitor (FAPI) radiotracers could address these challenges.</div></div><div><h3>Objective</h3><div>This review examines the association between pulmonary FAPI tracer uptake, fibrotic activity, and clinical parameters used for disease monitoring and prognostication in ILD to provide insights into its clinical potential.</div></div><div><h3>Methods</h3><div>In January 2025, a systematic literature search on PubMed, Ovid Medline, and Cochrane Library, utilizing the block-search strategy and snowballing, was conducted, and 13 studies were included.</div></div><div><h3>Results</h3><div>Both murine and human studies support that FAPI tracer uptake reflects fibrotic activity in ILDs, as uptake was consistently elevated in subject groups compared to controls. In murine ILD models, increased uptake was associated with fibrosis and fibroblast activation protein-α (FAP-α) expression upon histological examination. Uptake preceded the development of fibrosis on computed tomography (CT) and attenuated once fibrosis was established. In human ILD patients (Idiopathic pulmonary fibrosis (IPF) = 55, Connective tissue disease (CTD) ILD = 68, other ILDs = 55), FAPI uptake was localized to fibrotic lesions on high-resolution computed tomography (HRCT) and associated with increased FAP-α expression ex vivo. Uptake correlated with baseline pulmonary function tests (PFTs) and fibrosis extent on HRCT. Increased FAPI tracer uptake at baseline predicted disease progression upon follow-up.</div></div><div><h3>Conclusion</h3><div>An increasing body of evidence supports that FAPI tracers hold great clinical potential for the management of ILD by accurately monitoring fibrotic disease activity and identifying patients at risk of progression. Further research is required to confirm these findings.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103856"},"PeriodicalIF":9.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium","authors":"Otavio Cabral-Marques ,&nbsp;Lena F. Schimke ,&nbsp;Guido Moll ,&nbsp;Igor Salerno Filgueiras ,&nbsp;Adriel Leal Nóbile ,&nbsp;Anny Silva Adri ,&nbsp;Fernando Yuri Nery do Vale ,&nbsp;Júlia Nakanishi Usuda ,&nbsp;Yohan Lucas Gonçalves Corrêa ,&nbsp;Débora Albuquerque ,&nbsp;Roseane Galdioli Nava ,&nbsp;Ronaldy Santana Santos ,&nbsp;Haroldo Dutra Dias ,&nbsp;Hélio Fernandes Silva ,&nbsp;Pedro Batista Marconi ,&nbsp;Rusan Catar ,&nbsp;Michael Adu-Gyamfi ,&nbsp;Pinchao Wang ,&nbsp;Taj Ali Khan ,&nbsp;Alexander M. Hackel ,&nbsp;Gabriela Riemekasten","doi":"10.1016/j.autrev.2025.103855","DOIUrl":"10.1016/j.autrev.2025.103855","url":null,"abstract":"<div><div>The 5th International Symposium on Regulatory Autoantibodies Targeting GPCR (RAB-GPCRs) advanced the understanding of the significant role played by autoantibodies targeting G-protein-coupled receptors (GPCRs) in various human diseases. Once considered passive markers, RAB-GPCRs are now recognized as active modulators of cellular signaling, immune regulation, and inflammation. The symposium highlighted their involvement in multiple prominent pathologies, including autoimmune diseases, cardio- and cerebrovascular diseases, and neuroimmunologic disorders such as myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 syndrome (ME/CFS/PCS), as well as solid organ and hematopoietic stem cell transplantation (SOT/HSCT). Experts from rheumatology, immunology, and neurology presented interdisciplinary discussions on the potential of RAB-GPCRs as biomarkers and therapeutic targets. Advances in screening methods, biomarker identification, and therapeutic strategies were shared, emphasizing their diagnostic potential and application in novel therapeutic interventions. This report summarizes key insights from the symposium, particularly focusing on the modulatory properties of RAB-GPCRs and their relevance in both immune-mediated diseases and other pathologies (e.g., vascular, degenerative) that are traditionally not considered primarily immune-mediated. Ongoing research is expected to further establish these autoantibodies as crucial components in disease modulation and systems biology contexts, offering new opportunities for precision medicine and improved clinical outcomes in immune-related disorders.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103855"},"PeriodicalIF":9.2,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic evaluation of the associations between schizophrenia and autoimmune diseases: An umbrella review","authors":"Zhouyang Sun,&nbsp;Beibei Han,&nbsp;Qianlu Ding,&nbsp;Yuan Feng,&nbsp;Tingyi Jia,&nbsp;Yixin Ouyang,&nbsp;Xinru Guo,&nbsp;Jingyi Liang,&nbsp;Qianlong Huang,&nbsp;Changgui Kou ,&nbsp;Wei Bai","doi":"10.1016/j.autrev.2025.103854","DOIUrl":"10.1016/j.autrev.2025.103854","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to assess research trends in the association between schizophrenia and autoimmune diseases, systematically review their relationship, and evaluate the credibility of existing evidence.</div></div><div><h3>Methods</h3><div>Bibliometric analysis was conducted using the bibliometrix package in R, along with VOSviewer and CiteSpace. Relevant systematic reviews and meta-analyses were retrieved from six databases: PubMed, Web of Science, Embase, CINAHL, PsycINFO, and the Cochrane Library. Summary risk estimates were recalculated using the DerSimonian and Laird method under a random-effects model, and the credibility of the evidence was assessed.</div></div><div><h3>Results</h3><div>The bibliometric analysis found that “meta-analysis” has become a frequently used keyword and may be a focal point for future research. The umbrella review included 17 articles, containing 24 report data points from 12 quantitative reviews. Results indicated that 9 reports assessed the relationship between schizophrenia and autoimmune diseases. Schizophrenia was significantly associated with autoimmune neurological disorders <em>(RR</em> = 1.42; 95 % <em>CI</em> = 1.18–1.72), providing suggestive evidence. Seven reports evaluated the impact of schizophrenia on autoimmune diseases, showing highly suggestive evidence that schizophrenia patients had a pooled relative risk of 2.22 (95 % <em>CI</em> = 1.95–2.52) for psoriasis. Eight reports assessed the impact of autoimmune diseases on schizophrenia, with bullous pemphigoid patients showing significantly higher schizophrenia prevalence (<em>OR</em> = 2.63; 95 % <em>CI</em> = 2.03–3.39).</div></div><div><h3>Conclusions</h3><div>This study synthesizes evidence of varying levels, highlighting the association between schizophrenia and autoimmune diseases. It offers new insights for future exploration, fosters interdisciplinary collaboration, and provides valuable implications for public health policy development.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103854"},"PeriodicalIF":9.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}